OCA
VECT

Octagon Capital Advisors’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Octagon Capital Advisors’s Portfolio VECT Stock Details VECT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,259
Closed -$300K – 48
2023
Q1 		$300K Buy
+35,259
New +$291K 0.04% 35

Other funds holding VECT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Octagon Capital Advisors's VECT Position: Q2 2023 in Review

Octagon Capital Advisors sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q2 2023, closing a stake of 35,259 shares — an estimated $300K sold.

Octagon Capital Advisors first reported a position in VECT in Q1 2023 and held it in 1 quarter. The position peaked at $300K in Q1 2023. 49 funds tracked by Wall St. Rank hold VECT as of Q2 2023.

  • Octagon Capital Advisors reported no remaining VectivBio Holding AG Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 35,259 VectivBio Holding AG Ordinary Shares shares in Q2 2023, an estimated $300K.
  • Octagon Capital Advisors first reported a position in VectivBio Holding AG Ordinary Shares in Q1 2023 and held it in 1 quarter.
  • Octagon Capital Advisors's VectivBio Holding AG Ordinary Shares position peaked at $300K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q2 2023.

Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.